Tariq Mohammad

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

V. Libri, L. Huson, R. Festenstein, 2014, The Lancet.

ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors [Abstract]

J. Gribben, H. Gabra, S. Joel, 2013 .

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

V. Libri, L. Huson, R. Festenstein, 2014, The Lancet.